162 lines
48 KiB
Text
162 lines
48 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK23137">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK23137/?report=reader">
|
|
<meta name="ncbi_pagename" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/FES-M-4F-18F/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/p-MPPF18F/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2008/06/30">
|
|
<meta name="citation_author" content="Kenneth T. Cheng">
|
|
<meta name="citation_pmid" content="20641340">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK23137/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Kenneth T. Cheng">
|
|
<meta name="DC.Date" content="2008/06/30">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK23137/">
|
|
<meta name="description" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine ([18F]FPWAY) is a radioligand developed for positron emission tomography (PET) imaging of serotonin-1A (5-HT1A) receptors in the central nervous system (1, 2). It is a selective 5-HT1A antagonist labeled with 18F, a positron emitter with a physical t½ of 109.7 min (3, 4).">
|
|
<meta name="og:title" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine ([18F]FPWAY) is a radioligand developed for positron emission tomography (PET) imaging of serotonin-1A (5-HT1A) receptors in the central nervous system (1, 2). It is a selective 5-HT1A antagonist labeled with 18F, a positron emitter with a physical t½ of 109.7 min (3, 4).">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK23137/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/FPWAY18F/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK23137/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C8C407D63B4610000000000EB00C9.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK23137/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/FES-M-4F-18F/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/p-MPPF18F/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK23137/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK23137/&text=4-(2%B4-Methoxyphenyl)-1-%5B2%B4-(N-2%B4%B4-1%2C3%20pyrimidino)-p-%5B18F%5Dfluorobenzamido%5Dethyl..."><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK23137/?report=classic">Switch to classic view</a><a href="/books/NBK23137/pdf/Bookshelf_NBK23137.pdf">PDF (146K)</a><a href="/books/NBK23137/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK23137%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C8C407D63B4610000000000EB00C9.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK23137_"><span class="title" itemprop="name">4-(2´-Methoxyphenyl)-1-[2´-(<i>N</i>-2´´-1,3 pyrimidino)-<i>p</i>-[<sup>18</sup>F]fluorobenzamido]ethylpiperazine</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">[<sup>18</sup>F]FPWAY</div><p class="contribs">Cheng KT.</p><p class="fm-aai"><a href="#_NBK23137_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figFPWAY18FT1"><a href="/books/NBK23137/table/FPWAY18F.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figFPWAY18FT1" rid-ob="figobFPWAY18FT1"><img class="small-thumb" src="/books/NBK23137/table/FPWAY18F.T1/?report=thumb" src-large="/books/NBK23137/table/FPWAY18F.T1/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="FPWAY18F.T1"><a href="/books/NBK23137/table/FPWAY18F.T1/?report=objectonly" target="object" rid-ob="figobFPWAY18FT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="FPWAY18F.Background"><h2 id="_FPWAY18F_Background_">Background</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=FBWAY%201%2C3N%20OR%20FPWAY" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>4-(2´-Methoxyphenyl)-1-[2´-(<i>N</i>-2´´-1,3 pyrimidino)-<i>p</i>-[<sup>18</sup>F]fluorobenzamido]ethylpiperazine ([<sup>18</sup>F]FPWAY) is a radioligand developed for positron emission tomography (PET) imaging of serotonin-1A (5-HT<sub>1A</sub>) receptors in the central nervous system (<a class="bibr" href="#FPWAY18F.REF.1" rid="FPWAY18F.REF.1">1</a>, <a class="bibr" href="#FPWAY18F.REF.2" rid="FPWAY18F.REF.2">2</a>). It is a selective 5-HT<sub>1A</sub> antagonist labeled with <sup>18</sup>F, a positron emitter with a physical <i>t</i><sub>½</sub> of 109.7 min (<a class="bibr" href="#FPWAY18F.REF.3" rid="FPWAY18F.REF.3">3</a>, <a class="bibr" href="#FPWAY18F.REF.4" rid="FPWAY18F.REF.4">4</a>).</p><p>The serotonin (5-hydroxytryptamine (5-HT)) neurotransmission system consists mainly of neurons in the brainstem, with nerve tracts extending from these neurons to many areas of the brain and spinal cord. During firing, the neurons release 5-HT, a neurotransmitter that is involved in the modulation of various important physiologic functions and behavior, such as thermoregulation, cardiovascular function, aggressive and sexual behavior, mood, appetite, and the sleep–wake cycle. The effects of 5-HT are mediated by as many as seven classes of receptor populations (5-HT<sub>1</sub> to 5-HT<sub>7</sub>), many of which also contain several subtypes. There are five receptor subtypes within the G protein-coupled 5-HT<sub>1</sub> receptor family, with the 5-HT<sub>1A</sub> subtype located primarily in the limbic forebrain (the hippocampus, entorhinal cortex and septum). 5-HT<sub>1A</sub> receptors appear to function both as presynaptic (somatodendritic) autoreceptors in the raphe nuclei and as postsynaptic receptors in the terminal fields. This receptor subtype is involved in the modulation of emotion and the function of the hypothalamus, and is implicated in the pathogenesis of anxiety, depression, hallucinogenic behavior, motion sickness, dementia, schizophrenia, and eating disorders. A radioligand that can be used to assess the <i>in vivo</i> densities of 5-HT<sub>1A</sub> receptors and their changes may facilitate investigation of the relationship of these receptors to various neuropsychiatric diseases and aid in the design of novel drugs for their treatment.</p><p>Many psychiatric drugs modulate serotonergic transmission or specifically target the 5-HT<sub>1A</sub> receptors. Various compounds have been radiolabeled for visualization and quantification of these receptors. WAY 100635 was developed as a highly selective, silent antagonist (possessing no intrinsic agonist activity) of 5HT<sub>1A</sub> receptors at both pre- and postsynaptic sites. <a href="/books/n/micad/Carbonyl11C-WAY/?report=reader">WAY 100635</a> radiolabeled with <sup>11</sup>C at the carbonyl position is an effective radioligand but it is rapidly cleared and metabolized. The short <i>t</i><sub>½</sub> of <sup>11</sup>C also presents some challenges in clinical application of the radiotracer. A radioligand with slower metabolism and labeled with a longer-lived radioisotope would be a better agent for quantitative PET studies. A number of fluorinated derivatives of WAY 100635 have been developed. In 2000, Lang et al. (<a class="bibr" href="#FPWAY18F.REF.5" rid="FPWAY18F.REF.5">5</a>) synthesized [<sup>18</sup>F]FPWAY with labeling at the carboxamide moiety to minimize metabolites that cross the blood-brain barrier (BBB). [<sup>18</sup>F]FPWAY appears to be an intermediate-affinity antagonist of the 5-HT<sub>1A</sub> receptors and may be more sensitive to transient changes in endogenous 5-HT<sub>1A</sub> levels than high-affinity analogs (<a class="bibr" href="#FPWAY18F.REF.6" rid="FPWAY18F.REF.6">6</a>). In this WAY 100635 analog, the pyridine ring is replaced by pyrimidine and the cyclohexane ring is replaced by fluorobenzyl. With <sup>18</sup>F in the 4 position of the benzamide, [<sup>18</sup>F]FPWAY is a very different compound from another WAY 100635 analog with a similar abbreviation, <a href="/books/n/micad/F6PWAY18F/?report=reader">[<sup>18</sup>F]6FPWAY</a>, which was synthesized by Marchais et al. (<a class="bibr" href="#FPWAY18F.REF.7" rid="FPWAY18F.REF.7">7</a>). [<sup>18</sup>F]6FPWAY contains a N-pyridine with <sup>18</sup>F in the 6 position of the pyridine moiety.</p></div><div id="FPWAY18F.Synthesis"><h2 id="_FPWAY18F_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Lang et al. (<a class="bibr" href="#FPWAY18F.REF.5" rid="FPWAY18F.REF.5">5</a>, <a class="bibr" href="#FPWAY18F.REF.8" rid="FPWAY18F.REF.8">8</a>) first reported the synthesis of FPWAY based on FBWAY (or <i>p</i>-MPPF). FPWAY was synthesized as an FBWAY analog (FBWAY 1,3 N) with a 1,3 pyrimidine substituent. FBWAY was prepared by reacting WAY 100634 with the corresponding acid chloride in methylene chloride. Radiolabeling involved labeling the 4-trimethylamino precursor with <sup>18</sup>F to produce the radiolabeled 4-fluorobenzoyl chloride. The product was purified by high-performance liquid chromatography (HPLC). The radiochemical yield ranged between 10 and 20%, and the total synthesis time was between 80 and 90 min. The specific activity was 37,000 GBq (1,000 Ci)/mmol at the end of bombardment (EOB).</p><p>Ma et al. (<a class="bibr" href="#FPWAY18F.REF.9" rid="FPWAY18F.REF.9">9</a>) described a similar synthesis of FPWAY from {2-[4-(2-methoxyphenyl)-1-piperazinyl]-ethyl}-<i>N</i>-(2-pyrimidinyl)amine which was prepared from 2-[4-(2-methoxyphenyl)-1-piperazinyl]ethylamine (obtained commercially) by reaction with 2-chloropyrimidine in ethanol and sodium carbonate overnight. The yield was 79%. The final compound was reacted with 4-fluorobenzoyl chloride in triethylamine and 1,2-dichloroethane overnight to give a final yield of 96%. This precursor was reacted with [<sup>18</sup>F]− Kryptofix in dimethyl sulfoxide and heated in a microwave oven for 2 min. The product was purified by reverse-phase HPLC and a C-18 Sep-Pak to give a final yield of 25-35% EOB and radiochemical purity of 99.0%.</p></div><div id="FPWAY18F.In_Vitro_Studies_Tes"><h2 id="_FPWAY18F_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20in%20vitro%20studies" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p><i>In vitro</i> affinity of [<sup>18</sup>F]FPWAY was studied by Lang et al. (<a class="bibr" href="#FPWAY18F.REF.5" rid="FPWAY18F.REF.5">5</a>), and the inhibition constant, <i>K</i><sub>i</sub>, was determined to be <1 nM against [<sup>18</sup>H]8-hydroxy-2-dipropylaminotetralin ([<sup>3</sup>H]8-OH-DPAT) binding to a cloned cell line containing 5-HT<sub>1A</sub> receptors. This was relatively weak when compared with other high affinity WAY analogs (MeFWAY and Trans-FCWAY). The antagonist inhibition concentration (IC<sub>50</sub>)was determined to be 340 nM based on the compound’s ability to inhibit relaxation induced by 0.3 µM 8-OH-DPAT. On the basis of the compound’s ability to relax guinea pig field-stimulated ileum, the authors concluded that [<sup>18</sup>F]FPWAY showed no agonist activity.</p><p><i>In vitro</i> metabolism studies of FPWAY and [<sup>18</sup>F]FPWAY were performed by Ma et al. (<a class="bibr" href="#FPWAY18F.REF.9" rid="FPWAY18F.REF.9">9</a>) in cryopreserved hepatocytes of rat and human liver tissue. Metabolites were identified by liquid chromatography−tandem mass spectrometry. In rat hepatocytes, aromatic-ring oxidation was the major metabolism pathway for FPWAY, but there was also amide hydrolysis. Amide hydrolysis products were the major metabolites of FPWAY in human hepatocytes, and the metabolic rate appeared to be higher than for other fluorinated analogs of WAY 100635 (FBWAY and MeFBWAY). The study suggested that the pyrimidyl for pyridyl substitution in FPWAY made the amide more labile to metabolic hydrolysis. In a [<sup>18</sup>F]FPWAY imaging study using monkey blood, it was shown that pure [<sup>18</sup>F]FPWAY could be readily extracted by an organic phase (hexane−etyhl acetate 4:1) from its metabolites in a basic aqueous phase (125 mM KCl-NaOH, pH 12.5). This simplified the determination of the input function.</p></div><div id="FPWAY18F.Animal_Studies"><h2 id="_FPWAY18F_Animal_Studies_">Animal Studies</h2><div id="FPWAY18F.Rodents"><h3>Rodents</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Lang et al. (<a class="bibr" href="#FPWAY18F.REF.5" rid="FPWAY18F.REF.5">5</a>) studied the clearance of [<sup>18</sup>F]FPWAY from the rat brain by injecting the compound into rats. [<sup>18</sup>F]FPWAY appeared to have a two-component net efflux curve. Brain distribution and binding saturability were also determined in rats. The differential uptake ratios (DURs, calculated as % of injected dose x animal weight (g)/100) of [<sup>18</sup>F]FPWAY at 30 min were 0.403 ± 0.056 (<i>n</i> ≥ 4), 0.918 ± 0.107, and 0.141 ± 0.019 for the cortex, hippocampus, and cerebellum, respectively. When 200 nmol of WAY 100635 was co-injected along with [<sup>18</sup>F]FPWAY, the DURs decreased to 0.153 ± 0.040, 0.145 ± 0.040, and 0.131 ± 0.033 for the cortex, hippocampus, and cerebellum, respectively. The hippocampus/cerebellum ratios were 5.5 and 0.1 with and without 200 nM WAY 100635, respectively. The kinetic sensitivity (change in DUR per change in receptor concentration) of this compound appeared to be intermediate between FCWAY and FBWAY.</p><p>Jagoda et al. (<a class="bibr" href="#FPWAY18F.REF.10" rid="FPWAY18F.REF.10">10</a>) conducted autoradiography, biodistribution, and metabolite studies of [<sup>18</sup>F]FPWAY and other analogs ([<sup>18</sup>F]FCWAY and [<sup>18</sup>F]FBWAY) in rats and mice. The DURs (dose = 1850 kBq (50 µCi); <i>n</i> = 5) in rats at 30 min after injection for the hippocampus and cerebellum were 0.92 ± 0.11 and 0.14 ± 0.02, respectively. Their (hippocampus DUR/cerebellum DUR) − 1 ratio ((H/Cb) − 1) was 5.5. With the administration of WAY 100635 (200 nmol), the DURs for the hippocampus and cerebellum decreased to 0.14 ± 0.04 and 0.13 ± 0.03, respectively. The specific binding ratios (hippocampus/cerebellum) were 9, 4.6, and 0.1 for the mice of wildtype, heterozygotes, and receptor knockout mice, respectively. This showed that [<sup>18</sup>F]FPWAY bound specifically to the 5-HT<sub>1A</sub> receptors and was sensitive to changes in receptor density. Similar differences in localization patterns were observed in [<sup>18</sup>F]FPWAY autoradiography studies. The results from the blocking studies with WAY 100635 in rat and mouse brains were consistent with the fact that [<sup>18</sup>F]FPWAY possesses a lower 5HT<sub>1A</sub> receptor affinity than do high-affinity analogs. [<sup>18</sup>F]FPWAY regional bindings in the brains of “awake” mice showed no significant changes in response to treatments with paroxetine (a selective serotonin reuptake inhibitor) or fenfluramine (a serotonin transporter substrate and releasing agent). With use of the “chase” paradigm, a consistent pattern of changes of [<sup>18</sup>F]FPWAY regional brain binding in awake rats treated with fenfluramine or paroxetine was not observed. Urethane-anesthetized rats treated with fenfluramine also showed no significant changes in the specific binding ratios in the hippocampus. The study suggested that the <i>in vivo</i> serotonin system is tightly controlled so that changes in radioligand affinity alone might not produce significant changes in detection sensitivity for changes in endogenous 5-HT.</p></div><div id="FPWAY18F.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20%28dog%20OR%20rabbit%20OR%20pig%20OR%20sheep%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="FPWAY18F.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20%28primate%20NOT%20human%29" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Carson et al. (<a class="bibr" href="#FPWAY18F.REF.11" rid="FPWAY18F.REF.11">11</a>) studied the brain penetration of [<sup>18</sup>F]fluorobenzoic acid ([<sup>18</sup>F]FB), a major acid metabolite of [<sup>18</sup>F]FPWAY, in rhesus monkeys. PET imaging showed that [<sup>18</sup>F]FB crossed the BBB, but it did not have a significant effect on 5-HT<sub>1A</sub> receptor quantification of [<sup>18</sup>F]FPWAY. HPLC analysis of arterial blood samples also showed no metabolites when [<sup>18</sup>F]FB was injected.</p><p>Giovacchini et al. (<a class="bibr" href="#FPWAY18F.REF.6" rid="FPWAY18F.REF.6">6</a>) used PET imaging (10-40 min after injection) in rhesus monkeys to assess the response of [<sup>18</sup>F]FPWAY to dynamic <i>in vivo</i> changes in serotonergic neurotransmission caused by systemic administration of paroxetine. A dose of 259-518 MBq (7-14 mCi) of [<sup>18</sup>F]FPWAY (specific activity was 111 GBq (3 Ci/µmol) at time of administration), TOA) was given with a bolus-plus-infusion technique to achieve constant radioactivity in all brain regions. The distribution of radioactivity in the brain was consistent with the known concentrations of 5-HT<sub>1A</sub> receptors. The baseline binding potential (BP<sub>2</sub>) values of the raphe region, anterior cingulated, and frontal lobe were 0.53 ± 0.06, 1.90 ± 0.08, and 0.93 ± 0.08, respectively. Paroxetine administration (5 mg/kg) caused decreases of raphe BP<sub>2</sub>s ranging from 8 ± 6% during the first 30 min period to 27 ± 10% during the sixth 30-min period (180-240 min). On the other hand, cortical BP<sub>2</sub> values increased by 7 ± 3% during the first 30-min period and by 13 ± 5% during the second 30-min period, and then progressively decreased. The study suggested that dynamic changes in 5-HT<sub>1A</sub> neurotransmission could be quantified by [<sup>18</sup>F]FPWAY PET imaging.</p></div></div><div id="FPWAY18F.Human_Studies"><h2 id="_FPWAY18F_Human_Studies_">Human Studies</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%28FBWAY%201%2C3N%20OR%20FPWAY%29%20AND%20human" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No publication is currently available.</p></div><div id="FPWAY18F.NIH_Support"><h2 id="_FPWAY18F_NIH_Support_">NIH Support</h2><p>NIH Intramural Support. NIH Contract NO1MH2003.</p></div><div id="FPWAY18F.references"><h2 id="_FPWAY18F_references_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.1">Passchier J. , van Waarde A. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. <span><span class="ref-journal">Eur J Nucl Med. </span>2001;<span class="ref-vol">
|
|
<strong>28</strong>
|
|
</span>(1):113–29.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11202445" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11202445</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.2">McCarron J.A. , Pike V.W. , Halldin C. , Sandell J. , Sovago J. , Gulyas B. , Cselenyi Z. , Wikstrom H.V. , Marchais-Oberwinkler S. , Nowicki B. , Dolle F. , Farde L. The pyridinyl-6 position of WAY-100635 as a site for radiofluorination--effect on 5-HT1A receptor radioligand behavior in vivo. <span><span class="ref-journal">Mol Imaging Biol. </span>2004;<span class="ref-vol">
|
|
<strong>6</strong>
|
|
</span>(1):17–26.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15018825" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15018825</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.3">Bantick R.A. , Rabiner E.A. , Hirani E. , de Vries M.H. , Hume S.P. , Grasby P.M. Occupancy of agonist drugs at the 5-HT1A receptor. <span><span class="ref-journal">Neuropsychopharmacology. </span>2004;<span class="ref-vol">
|
|
<strong>29</strong>
|
|
</span>(5):847–59.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14985704" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14985704</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.4">Karramkam M. , Hinnen F. , Berrehouma M. , Hlavacek C. , Vaufrey F. , Halldin C. , McCarron J.A. , Pike V.W. , Dolle F. Synthesis of a [6-pyridinyl-18F]-labelled fluoro derivative of WAY-100635 as a candidate radioligand for brain 5-HT1A receptor imaging with PET. <span><span class="ref-journal">Bioorg Med Chem. </span>2003;<span class="ref-vol">
|
|
<strong>11</strong>
|
|
</span>(13):2769–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12788351" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12788351</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.5">Lang L. , Jagoda E. , Schmall B. , Sassaman M. , Ma Y. , Eckelman W.C. Fluoro analogs of WAY-100635 with varying pharmacokinetics properties. <span><span class="ref-journal">Nucl Med Biol. </span>2000;<span class="ref-vol">
|
|
<strong>27</strong>
|
|
</span>(5):457–62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10962250" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10962250</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.6">Giovacchini G. , Lang L. , Ma Y. , Herscovitch P. , Eckelman W.C. , Carson R.E. Differential effects of paroxetine on raphe and cortical 5-HT1A binding: a PET study in monkeys. <span><span class="ref-journal">Neuroimage. </span>2005;<span class="ref-vol">
|
|
<strong>28</strong>
|
|
</span>(1):238–48.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15993625" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15993625</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.7">Marchais S. , Nowicki B. , Wikstrom H. , Brennum L.T. , Halldin C. , Pike V.W. Short and efficient syntheses of analogues of WAY-100635: new and potent 5-HT1A receptor antagonists. <span><span class="ref-journal">Bioorg Med Chem. </span>2001;<span class="ref-vol">
|
|
<strong>9</strong>
|
|
</span>(3):695–702.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11310604" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11310604</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.8">Lang L. , Jagoda E. , Schmall B. , Vuong B.K. , Adams H.R. , Nelson D.L. , Carson R.E. , Eckelman W.C. Development of fluorine-18-labeled 5-HT1A antagonists. <span><span class="ref-journal">J Med Chem. </span>1999;<span class="ref-vol">
|
|
<strong>42</strong>
|
|
</span>(9):1576–86.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10229627" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10229627</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.9">Ma Y. , Lang L. , Kiesewetter D.O. , Eckelman W.C. Liquid chromatography-tandem mass spectrometry identification of metabolites of three phenylcarboxyl derivatives of the 5-HT(1A) antagonist, N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl) trans-4-fluorocyclohexanecarboxamide (FCWAY), produced by human and rat hepatocytes. <span><span class="ref-journal">J Chromatogr B Analyt Technol Biomed Life Sci. </span>2002;<span class="ref-vol">
|
|
<strong>780</strong>
|
|
</span>(1):99–110.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12383485" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12383485</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.10">Jagoda E.M. , Lang L. , Tokugawa J. , Simmons A. , Ma Y. , Contoreggi C. , Kiesewetter D. , Eckelman W.C. Development of 5-HT(1A) receptor radioligands to determine receptor density and changes in endogenous 5-HT. <span><span class="ref-journal">Synapse. </span>2006;<span class="ref-vol">
|
|
<strong>59</strong>
|
|
</span>(6):330–341.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16440292" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16440292</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="FPWAY18F.REF.11">Carson R.E. , Wu Y. , Lang L. , Ma Y. , Der M.G. , Herscovitch P. , Eckelman W.C. Brain uptake of the acid metabolites of F-18-labeled WAY 100635 analogs. <span><span class="ref-journal">J Cereb Blood Flow Metab. </span>2003;<span class="ref-vol">
|
|
<strong>23</strong>
|
|
</span>(2):249–60.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12571456" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12571456</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK23137_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Kenneth T. Cheng</span>, PhD<div class="affiliation small">
|
|
National Center for Biotechnology Information, NLM, NIH, Bethesda, MD,
|
|
<span class="before-email-separator"></span><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a>
|
|
</div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">February 1, 2005</span>; Last Update: <span itemprop="dateModified">June 30, 2008</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Cheng KT. 4-(2´-Methoxyphenyl)-1-[2´-(N-2´´-1,3 pyrimidino)-p-[18F]fluorobenzamido]ethylpiperazine. 2005 Feb 1 [Updated 2008 Jun 30]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/FES-M-4F-18F/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/p-MPPF18F/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobFPWAY18FT1"><div id="FPWAY18F.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK23137/table/FPWAY18F.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__FPWAY18F.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4-(2´-Methoxyphenyl)-1-[2´-(<i>N</i>-2´´-1,3 pyrimidino)-<i>p</i>-[<sup>18</sup>F]fluorobenzamido]ethylpiperazine</td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>18</sup>F]FPWAY</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[<sup>18</sup>F]FBWAY 1,3 N<br />4-[<sup>18</sup>F]-Fluoro-<i>N</i>-{2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl}-<i>N</i>-(2-pyrimidinyl)benzamide</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Compound</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5-HT<sub>1A</sub> receptors</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor-ligand binding</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Positron emission tomography (PET)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal/contrast:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><sup>18</sup>F</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Non-primate non-rodent mammals
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Non-human primates
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Humans
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click on the above structure for additional information in <a href="http://pubchem.ncbi.nlm.nih.gov" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubChem</a>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|